This company listing is no longer active
Amryt Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Amryt Pharma has a total shareholder equity of $324.3M and total debt of $208.6M, which brings its debt-to-equity ratio to 64.3%. Its total assets and total liabilities are $736.9M and $412.6M respectively.
Key information
64.3%
Debt to equity ratio
US$208.60m
Debt
Interest coverage ratio | n/a |
Cash | US$83.25m |
Equity | US$324.28m |
Total liabilities | US$412.60m |
Total assets | US$736.88m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 3N9A's short term assets ($224.4M) exceed its short term liabilities ($143.1M).
Long Term Liabilities: 3N9A's short term assets ($224.4M) do not cover its long term liabilities ($269.5M).
Debt to Equity History and Analysis
Debt Level: 3N9A's net debt to equity ratio (38.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 3N9A's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 3N9A has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 3N9A is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 45.1% per year.